About Novotech
Novotech is the largest clinical research organisation focused exclusively on the Asia-Pacific region, providing full-service CRO capabilities to biotechnology and pharmaceutical companies seeking to run trials in markets that are often critical to global regulatory strategies.
Founded in 1996 and headquartered in Sydney, Australia, Novotech operates across more than 30 countries throughout Asia-Pacific, including Australia, China, Japan, South Korea, Singapore, Taiwan, and India. Its geographic focus gives sponsors access to large, treatment-naive patient populations, experienced principal investigators, and regulatory pathways, particularly the Australian Clinical Trials framework, which allows Phase I studies to begin without prior regulatory approval from the Therapeutic Goods Administration.
The company delivers Phase I through Phase IV clinical trial services, including biostatistics, data management, regulatory affairs, medical writing, and pharmacovigilance. Novotech has particular depth in oncology, rare diseases, and infectious diseases, and has worked with hundreds of emerging biotech sponsors as well as established pharmaceutical companies. Its client base is weighted towards North American and European sponsors seeking an efficient entry into Asia-Pacific development programmes.
Novotech has expanded its service offering through strategic acquisitions and partnerships, strengthening its laboratory, early-phase, and regulatory consulting capabilities. The company positions itself as a specialist alternative to global full-service CROs for sponsors whose development priorities require Asia-Pacific expertise at the centre of their trial strategy rather than as a peripheral geography.
Further information is available at novotech-cro.com.
